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Abstract: Nine years of experience with 2286 commercial synthesis allowed us to deliver comprehensive informa-
tion on the quality of 18F-FDG production. Semi-automated FDG production line using Cyclone 18/9 machine (IBA 
Belgium), TRACERLab MXFDG synthesiser (GE Health, USA) using alkalic hydrolysis, grade “A” isolator with dispensing 
robotic unit (Tema Sinergie, Italy), and automatic control system under GAMP5 (minus2, Slovakia) was assessed by 
TQM tools as highly reliable aseptic production line, fully compliant with Good Manufacturing Practice and just-in-
time delivery of FDG radiopharmaceutical. Fluoride-18 is received in steady yield and of very high radioactive purity. 
Synthesis yields exhibited high variance connected probably with quality of disposable cassettes and chemicals 
sets. Most performance non-conformities within the manufacturing cycle occur at mechanical nodes of dispensing 
unit. The long-term monitoring of 2286 commercial synthesis indicated high reliability of automatic synthesizers. 
Shewhart chart and ANOVA analysis showed that minor non-compliances occurred were mostly caused by the dec-
linations of less experienced staff from standard operation procedures, and also by quality of automatic cassettes. 
Only 15 syntheses were found unfinished and in 4 cases the product was out-of-specification of European Phar-
macopoeia. Most vulnerable step of manufacturing was dispensing and filling in grade “A” isolator. Its cleanliness 
and sterility was fully controlled under the investigated period by applying hydrogen peroxide vapours (VHP). Our 
experience with quality assurance in the production of [18F]-fluorodeoxyglucose (FDG) at production facility of BIONT 
based on TRACERlab MXFDG production module can be used for bench-marking of the emerging manufacturing and 
automated manufacturing systems.
Keywords: (18F)-fluorodeoxyglucose (FDG), good manufacturing practice, quality assurance, quality control, total 
quality management
Background
FDG production site facility was built in recon-
structed building of Slovak metrological insti-
tute, Bratislava within the years 2001-2004 
when various quality assurance systems were 
introduced, the pharmaceutical quality in par-
ticular [1-7]. In our country no precedence exist-
ed in the field of radiopharmaceutical produc-
tion. Still, our “specific” investor, which was the 
Slovak Office of Standards, Testing and 
Metrology, to receive our future licensees and 
clients’ credit required the user request specifi-
cation and the design qualification in compli-
ance with all more or less relevant European 
and world quality management standards [8, 
9], stressing the rules of Good Manufacturing 
Practice (GMP), Good Automated Manufacturing 
Practice (GAMP), Good Practice of Control 
Laboratories (GPCL) and Good Distribution 
Practice (GDP). Quality management system of 
company according ISO 9001 standard has 
been certified since 2007 by the Lloyd’s 
Register EMEA (Prague Office).
Our experience of FDG commercial manufactur-
ing may be useful for benchmarking and evalu-
ation of improvements in this field. Principal 
decisions on FDG production approach are pre-
dictable in near future due to a paradigm shift 
and competition between central manufactur-
ing and in-house preparation schemes, reduc-
ing size and complexity of equipment required 
and the process cost, but still encountering 
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GMP demands of parametrically controlled 
aseptic production and pharmaceutical quality 
control.
Clean rooms
Clean rooms were designed by company BLOCK 
(Prague/Valašské Meziříčí, Czech Republic).
The dilemma of the operator protection by 
under pressure in the area of radioactive 
source and overpressure of clean air around 
the devices for pharmaceutical processing was 
solved during the design qualification. Class III/
IV tightness (ISO 10648-2:1994) shielded cells 
with closed synthesis modules, were adjusted 
for class “C” (ISO class 7) housing. Pressure 
drop cascades in production area [10] ensured 
radiation protection against radio aerosols 
transfer from shielded boxes to operation 
rooms, and microbiological and particulate 
contamination from class “D” to class “C”.
The commercial devices dedicated to automat-
ed dispensing in air grade “A” (ISO class 5) 
aseptic environment passed scrupulous design 
qualification and operational qualification pro- 
cedures.
Automatic synthesizer
ISO and GMP compliant housing for about 1 
TBq positron (PET) radiopharmaceuticals syn-
Quality control
Analytical methods were validated and periodi-
cally (at least once per year) re-validated to 
obtain type B standard deviation of method 
[11], and analytical results were assessed 
using expanded uncertainty with the coverage 
factor which is equal appropriately k(α) = 2 for 
probability α = 0.95. No out-of-specification 
(OOS) [12, 13] results were obtained.
Dispensing
The dispensing units available at the European 
market (year 2003) did not pass the external 
design qualification whose aim was to avoid ter-
minal sterilization and ensure aseptic filling of 
radiopharmaceuticals into open vials (without 
septum puncture), with continuous particle 
monitoring and microbial probing, and conse-
quently enabling in-situ bubble point tests of 
sterilization membrane. Further, it was required 
to enable identification of vials, measure vol-
ume and activity of radiopharmaceutical in 
standard vials, and communicate with produc-
tion information system both on stage of pro-
gramming the dispensing regime and at distrib-
uting information for radiopharmaceutical 
certificate. 
Under the IAEA technical co-operation project, 
an isolator type shielded laminar box with dou-
Table 1. Radioactive purity of 18F
Nuclide Half-life
Activity calibrated at EOB
Irradiated water Recovery water Bulk FDG solution
Bq/g ppb Bq/g ppb Bq/g ppb
F-18 110 m 6.3×1010 - 6.5×1010 - 4.5×1010 -
Cr-51 27.7 d 5113 81 747 12 <10 <0.22
Mn-52 5.59 d 1479 24 958 15 <2 <0.03
Mn-54 312 d 80 1.3 60 1 <2 <0.03
Co-55 17.5 h 6657 106 14003 215 <0.6 <0.01
Co-56 7.73 d 1562 25 2074 32 <2 <0.04
Co-57 272 d 743 12 1119 17 <2 <0.04
Co-58 70.9 d 9428 150 12104 186 <2 <0.04
Ni-57 1.48 d 3477 55 4641 71 <2 <0.05
Tc-95 20 h 709 11 N.D. N.D. N.D. N.D.
Tc-95 m 60 d 100 1.6 N.D. N.D. N.D. N.D.
Tc-96, 96 m 4.28 d 317 5 N.D. N.D. N.D. N.D.
Re-181 1.27 y 141 2 <47 <0.7 <1.7 <0.04
Re-182, 182 m 19.9 h 269 4 <90 <1.4 <5.0 <0.11
Re-183 2.67 d 134 2 <79 <1.2 <4.2 <0.09
N.D. - not detectable.
thesis modules under class 
“C” was designed as:
- Atmosphere class “C” 
according EEC GMP, - verti-
cal laminar flow (ISO 
14644-3e NSF 49), - air-
tight doors validated at 
negative pressure below 
10 Pafor 12 hrs (contain-
ment enclosure tests for 
class “2” according to (ISO 
10648-2:1994), - particle 
and microbial monitoring of 
inner atmosphere is possi-
ble, - the inner surfaces 
should be easily cleaned 
and disinfected by aggres-
sive disinfection means, 
desirable also sterilisable 
(stainless steel AISI 316 
preferred), - aeriform waste 
control, automatic closure 
of outlet air ducts.
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Table 2. Average pharmaceutical quality of Biont FDG from 2286 commercial batches
Specification Test method* Limits
Declared activity 18F (%) IC 90-110
18F half-life (min) IC 105-115
Radionuclidic purity of 18F GS >99.9
Concentration of 2-fluoro-2-deoxy-D-glucose (mg/ml)* HPLC ≤0.05
Concentration of Kryptofix® 222 (mg/ml)* colorim. ≤0.22
Radiochemical purity of 2-[18F]-fluoro-2-deoxy-D-glucose, with less than 10% fraction of 2-[18F]-fluoro-2-deoxy-D-mannose (%) HPLC ≥95.0
Radiochemical impurities of [18F] fluoride and acetylated 2-[18F]-fluoro-2-deoxy-D-glucose and 2-[18F]-fluoro-2-deoxy-D-mannose (%) TLC ≤5.0 
Concentration of glucose (mg/ml) HPLC ≤0.63
Concentration of acetonitrile (mg/ml)**** GC ≤0.41
Concentration of ethanol (mg/ml)**** GC ≤5
Radionuclide impurities (%)**** GS <0.1%
Bacterial endotoxins (EU/ml)**** LAL <17.5
Sterility**** Ph.Eur. 2.6.1 No CFU
*IC-ionisation chamber (dose calibrator), GS-gamma-ray spectrometry, GC-gas chromatography, HPLC-high-performance liquid chromatography, TLC-thin layer chromatography, LAL-
Limulus Amebocytus Lysate test. **Expanded uncertainty with the coverage factor which is equal appropriately k(α) = 2 for probability α = 0.95. ***The compliance for the maximum 
recommended dose V = 10 ml. ****The result of test are appended in a due time after the production, the injection may be released for use before completion of this part of analy-
sis.
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ble door material transfer system (LaCalhén 
type) was constructed. Its construction materi-
als should withstand the hydrogen peroxide 
vapours (VHP) and a laminar flow protects the 
dispensing unit housing also in open state.
The user request specification was formulated 
like follows:
An aseptic robotize dispensing unit housed in a 
shielded isolator of grade “A” at rest (ISO 
14644-1 class 4.8) for automatic formulation 
(adjustment of strength of sterile radioactive 
product by dilution with sterile excipient solu-
tion up to 1:10) and dispensing in the batch of 
15-25 open sterile and apyrogenic 10-15 ml 
vials (ISO 8362-1:1990), identified by a bar 
code, preferentially without necessity of final 
thermal sterilisation of radiopharmaceutical 
and ensuring its volume radioactivity standard 
deviation less than 5% and volume accuracy 
better than 2% with - manipulation with prepa-
ration of sterile components without breaking 
containment (e.g. sleeve system in inner poly-
methylmetacrylate/polycarbonate glass front 
door), - a 0.4-0.5 m/s laminar flow of controlled 
temperature <30°C and relative humidity <60% 
in working area, - the radiation shielding for a 
safe work with 220 GBq (6 Ci) of fluorine-18 in 
automatic dispensing regime, - tightness mini-
mum of class 3 according to ISO 10648-2, 
internal pressure control, - a standard opera-
tion procedure of the sterilization-in-place of 
the equipment and its housing, desirable with 
the vapours of hydrogen peroxide (VHP), - per-
formance of the on-line bubble point test of 
sterilization membrane integrity, - a safe pass-
through for input of sterile materials according 
An offer of Tema Sinergie company was a win-
ner of the IAEA tender among five companies, 
and the isolator construction was finished 
under the IAEA technical cooperation program 
SLR/2/002.
Production monitoring system
A daily batch production is accompanied by the 
stock of documents, which are similar to those 
of any large-scale drug production. 
The requirements of 21 CFR Part 11, GAMP4 
[14, 15] and GAMP5 were implanted in the 
information system ensuring registration 
according to GMP and ISO 9001 rules and 
using encryption algorithms MD5-SHA1 for the 
on-line processes documentation, starting with 
the order acceptance till the issues of delivery 
documents. The system minimizes or controls 
subjects influence on records, keeping the hard 
copies down to those required by FDG authori-
zation. Electronic forms of documents are kept 
under system Alfresco [16].
Yields of FDG were calculated from the activity 
delivered from target to synthesis module and 
resulting FDG solution, controlled by certified 
dose calibrator (Canberra-Packard). Cross-
checking of FDG strength was monitored by 
another certified device in quality control.
Data treatment
A technical graphing program SigmaPlot® 4.0 
for Windows (SPSS Inc., Chicago) was used for 
statistical evaluations and data presentation. 
Table 3. Delivery compliance of commercial batches of FDG
Year Total
Delayed Not completed batch dispensing Cancelled
Total com-
pliance
Number % Number % Number % %
2006 203 4 2.0 0 0 17 8.4 89.7
2007 259 9 3.5 9 3.5 0 0.0 93.1
2008 244 8 3.3 4 1.6 2 0.8 94.3
2009 176 18 10.2 4 2.3 3 1.7 85.8
2010 336 13 3.9 12 3.6 6 1.8 90.8
2011 230 7 3.0 0 0 1 0.4 96.5
2012 249 8 3.2 2 0.8 1 0.4 96.5
2013 274 2 0.7 12 4.4 1 0.4 94.5
2014 315 14 4.4 26 8.3 3 1.0 86.3
Total 2286 83 3.6 69 3.0 34 1.5 91.9
to ISO 14644-7 (desirable 
Double Door Rapid Transfer 
Port, DPTE system), - access 
sampling points for in-oper-
ation microbial and airborne 
particles monitoring of gr- 
ade “B” cleanliness, - an 
output of capped labelled 
vials without breaking the 
aseptic conditions in 2 cm 
lead containers from the 
front/rear side of shielded 
cell, - all prophylactic ser-
vice of isolator available 
outside the grade “C” oper-
ator room.
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Results and discussion
Activation process
Cyclotron itself is usually not considered as a 
part of GMP equipment [5], however e.g. in 
case of FDG its product of activation, 18F is a 
raw material for 18F-radiopharmaceutical syn-
thesis [7]. We included monitoring of cyclotron 
in our on-line control as a part of our total qual-
ity control [10, 17-19].
As a basic parameter we choose the initial yield 
of activation m (GBq/mA), calculated as
(1 )I e
A e
1
2
2
t
t
=
-n -m
m
                                               (1)
where A2 (GBq) is activity of radionuclide (decay 
constant l) measured at beginning of synthesis 
(BOS), I is beam intensity (μA) during the time of 
irradiation t1, and t2 (the least two being 
λ-coherent time units) is time between EOB and 
BOS. Such complex parameter may be influ-
enced by quality of the cyclotron beam and the 
yield of 18F delivered into synthesis module 
(and influenced e.g. by concentration of 18O in 
target water and adsorption of 18F on target and 
transport capillaries walls or on filterable colloi-
dal particles).
For assessment of process quality we adopted 
methodology from the Six Sigma quality system 
[13, 20], namely applying the “process capabil-
ity index”
min 3
L
; 3C
LS USL
pk =
- -
v
n
v
n$ .                          (2)
This index is considered as a good indicator of 
process quality, if Cpk is above 1.33 and better 
above 1.5 (when USL-LSL≥6σ). This index 
strongly depends on the choice of lower specifi-
cation and upper specification level, LSL and 
USL respectively (Figures 1, 2). Choice of USL 
is reasonable to derive from a maximal beam 
permissible for given target construction and 
LSL can be formulated from practical task to 
produce required activity in a reasonable time 
(see also the part „In-time delivery“ below). For 
our assessment their values were based on the 
first series of cyclotron monitoring when m = 
8.12 GBq/mA and standard deviation s = 
0.035 m were obtained (relative deviation of m 
3, 5%). The limits LSL = 7.56 and USL = 8.68 
were chosen, i.e. the width of <LSL;USL> inter-
val was 4σ instead of 6σ, because the aim was 
not to control a high reproducibility of activation 
yield, which is not of crucial importance here, 
but to get a suitable indicator for discovery of 
more serious process deviations and non-com-
pliances concerning beam deformation or targ-
etry state.
The two last year’s monitoring of activation 
process capability (Figure 3) indicated high 
reliability of cyclotron performance, just 12 
deviations and non-compliance 2.1% took 
place.
As an example of exploitation of “warning” 
capability index there was extra thorough 
review of the activation exhibiting the most neg-
Figure 1. Modelled capability index of activation at 
specification limit USL-LSL = 11σ.
Figure 2. Modelled capability index of activation at 
specification limit USL-LSL = 4σ.
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ative value of Cpk. It this case the amount of 
activity prepared for synthesis was as planned, 
however a non-standard break in irradiation (9 
min from 90 minutes of total production time) 
happened and was reflected in the negative Cpk 
value as a signal of the process declination 
from a standard procedure of target activation. 
Though the operator‘s corrective actions were 
fully effective in this situation, still some pre-
ventive measures should have been consi- 
dered.
Radioactive purity of 18F
The radionuclide composition of irradiated 
water in niobium target, and radionuclide purity 
of recovery water and bulk FDG solution was 
measured in 2 g samples. The targets with 
heavy-duty history of foils were chosen to maxi-
mise possible impurities content. The samples 
containing originally 63-65 GBq of 18F were left 
to for the decay of the latter and measured by 
HPGe crystal (type GC3519, 35% efficiency, 
resolution 1.9 keV at 1.33 MeV) and analysed 
by a DSA-2000/A digital spectra analyser 
Canberra-Packard with S501/C Genie-2000 
and S505 quality assurance software. The 
activity found was extrapolated to the EOB 
time. Relative uncertainty of counting was not 
higher than 20%, and lower limit of impurities 
detection (LLD) was determined for each uncer-
tain data. 
The results of these tests showed clearly that 
most of the possible contaminants are recov-
ered in the 18O enriched water waste and do not 
enter into the synthesis process. The activity 
measurement on the FDG solution is presented 
for the bulk solution before dilution, the activity 
level after saline dilution will be even three to 
seven times lower in the final solution (Table 1).
Major activation products in niobium target are 
isotopes of cobalt (Co-55 and 58) and chromi-
um (Cr-51), and also Mn-52, Ni-57 and Tc-95. 
Except the lower amounts of Co-56, and Tc-96 
(and absence of Cd-109 originated from silver 
body), the list of impurities relates to the same 
radionuclides as obtained at activation in a sil-
ver target, indicating their origin from Havar 
alloy foil [21]. Most of radioactivity impurities 
remain in the solution, which pass the quater-
nary ammonium resin column for separation of 
fluorine-18 with impurities of chromium, man-
ganese, technetium and rhenium. The latter 
are completely removed on the steps of FDG 
synthesis and purification and do not appear in 
the bulk solution of FDG product above limit of 
their detection (LOD), i.e. maximal content of 
radioactive impurities in resulting bulk FDG 
solutions was estimated as low as 7×10-8 % at 
EOS.
Figure 3. Two-years data for capability index of acti-
vation of 18F on Cyclone 18/9 niobium target.
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Synthesis yields
The yields corrected on radioactive decay 
(chemical yields) for the sets of 300-2400 syn-
thesis failed at Kolmogorov-Smirnov normality 
tests. The mean value and their standard devi-
ation calculated for symmetrical distribution for 
the first 1320 FDG batches in years 2006-
2010 was 68±22%, while the 1082 batches in 
years 2011-2014, performed at doubled BOS 
No significant influence of target body (silver or 
niobium) on chemical yield was observed. Also 
the losses of activity in target body and PEEK 
capillary were found to be less than 5%.
By two-ways ANOVA analysis it appeared that 
the operators skills were found of a minor influ-
ence on synthesis yield [13] in opposite to the 
“stationary” system represented e.g. by TR- 
ACERlab FXFDG module [22]. It was difficult to 
distinguish influence of quality of sets of chemi-
cals and the module disposable cassettes 
(both ABXadvanced biochemical compounds 
GmbH). However, by all-pairwise multiple com-
parison Holm-Sidak method it appeared that 
the cassettes’ quality was almost certainly sig-
nificant and it was further confirmed by an inter 
laboratory review. The reason was probably in 
humidity contents in the cassettes.
It may be remarked, that the statistical 
approach (the ANOVA analysis and Shewhart 
diagrams discussed above) and vendors’ audit 
are practically the only way of feasible input 
materials quality control. Reliable physical test-
ing of small sets of chemicals, cassettes and 
packing materials is economically not bearable 
and manufacturer should rely on output quality 
control at the site of suppliers [10].
Figure 4. Normality test for corrected (chemical) yield of FDG from TRACER-
lab MXFDG synthesizer.
Figure 5. Tukey plot of chemical yield of FDG from 
TRACERlab MXFDG synthesiser for different operators.
activities (average 221 GBq 
BOS, compared with 113 GBq 
of the former set) provided 
the yield value 50±12%. 
Normality plot for total set of 
data is presented in Figure 4. 
Under conditions of symmet-
ric distribution of all data, the 
chemical yield was formally 
56±11% but the whole set 
distribution skewness is 3.26 
(a long tail to the right of sym-
metrical distribution for which 
a skewness is zero) and kurto-
sis 63.2 (leptokurtic distribu-
tion, more “peaked” than a 
Gaussian distribution for wh- 
ich a kurtosis of 3 is valid). 
Therefore, further attention 
was paid to influence of targ-
etry, activity, operators, sets 
of chemicals (mannose tri-
flate in particular) and dispos-
able synthesis cassettes (Fi- 
gures 5 and 6). 
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Further, influence of activity on the radioactive 
decay corrected (chemical) yield and radio-
chemical purity of FDG is demonstrated by 
Figures 7 and 8. As can be expected conferring 
high radiation stability of FDG [23, 24], the 
radiochemical purity is not extensively influ-
enced by the activity of fluorine-18 at the BOS. 
When presented by linear regression, decreas-
ing of radiochemical purity of FDG due to 
increasing activity at BOS can be expected as 
low as 0.5 percentage points. At the same time, 
influence of BOS activity on chemical yield was 
expressed more strongly and the extrapolat- 
ing to European Pharmacopeia [7] and follow-
ing out-of-specification criteria [12, 19].
Automatic dispensing
The operation qualification (OQ) of dispensing 
unit was confirmed by 48 dispensing runs of in-
raw dispensing 15-25 ml of sterile physiological 
solution into 7-10 sterile crimped 10R (ISO 
8362-1:1990) vials from 50 total without any 
fatal (i.e. in-correctable within real time of 10 
min) fault, i.e. each batch was dispensed into 
7-10 vials, and the crimped vials with sterile 
Figure 6. Shewhart control chart.
Figure 7. Chemical yield of 18F-FDG as a function of initial (BOS) activity.
ed “zero-activity” yield 64% 
may be diminished to about 
38% expectation at the BOS 
activity 500 GBq. Manu- 
facturer’s declared parame-
ters of TRACERlab MXFDG mod-
ules are for typical average 
chemical (decay corrected) 
yield 70±4%, independent of 
starting activity level up to 10 
Ci, and radiochemical purity 
better than 99.5% [25]. 
Quality parameters
Product sterility and apyro-
genity, the most important 
parameters when considering 
the risk management of diag-
nosed patient, should have 
been ensured by manufac- 
turing scheme parameters. 
During the whole manufactur-
ing period no unsterile prod-
uct was detected. Also the 
sensitive apyrogenity test 
showed that the average bac-
terial, endotoxins concentra-
tion was deep below the phar-
macopoeial limit for intrave- 
nous applications (Table 2).
Increased attention to the 
FDG quality has been paid at 
our PET centre yet during 
manufacturing preparation 
period, since its purchase 
delivery from UJF original mar-
keting authorization holder 
(MAH) from Prague took about 
4-5 hours [23, 24].
Routine manufacturing FDG 
quality was assessed accord-
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solution were delivered to small containers 
from DMC 3/75 shielded isolator. Apyrogenity 
test was performed on the day of filling, the ste-
rility test was performed by authorised Slovak 
company one week after filling, both for the first 
and last vial from each run. Neither pyrogenic 
nor non-sterile vials content was found during 
the OQ.
In-time delivery
In-time delivery is a very important factor for 
medical clients and their patients, its USL being 
much below the expiration time of FDG (8-10 
hrs from EOS in our case).
pensing unit, synthesis modules, shielding 
boxes and cyclotron (targets and capillaries) 
(Figure 10).
Conclusions
Semi-automated FDG production line using 
Cyclone 18/9 machine (IBA Belgium), TRA- 
CERLab MXFDG synthesiser (GE Health, USA) 
using alkalic hydrolysis, grade “A” isolator with 
dispensing robotic unit (Tema Sinergie, Italy), 
and automatic control system under GAMP5 
(minus2, Slovakia) was assessed by TQM tools 
as highly reliable aseptic production line, fully 
compliant with Good Manufacturing Practice 
Figure 8. Radiochemical purity of 18F-FDG as a function of initial (BOS) activ-
ity.
Figure 9. In-time delivery indicator of quality.
We choose reference time for 
“ready-for-QC” from interval t 
= <t1-25;t1+40> where t1 is 
official planned time (min) of 
finished dispensing according 
the order for FDG manufactur-
ing. A 40-minutes delay was 
considered to be acceptable 
by clients and too early perfor-
mance, 25 minutes before 
official time was considered 
too early and unfavourable 
due to require excess of raw 
fluorine-18. Only few of manu-
facturing cycles 1.6% were 
outside of these tolerable lim-
its (Table 3, Figure 9). 
Dependability of manufactur-
ing segments
Deviations and non-compli-
ances of basic segments of 
manufacturing processes:
● Materials supplies, ● cyclo-
tron performance, ● targets 
and transport capillaries, ● 
radiation monitoring, ●HVAC, 
● shielding boxes, ● synthe-
sisers, ●dispensing unit, and 
● delivery
were registered and reported 
by operators on-line to be 
subject of correction actions 
in real time and/or preventive 
actions in future.
Majority of non-compliances 
was connected with the 
mechanical operations in dis-
18F-FDG production quality
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and just-in-time delivery of FDG radiopharma-
ceutical. The stages of nuclear activation and 
synthesis are not sensitive to operator’s perfor-
mance. Fluoride-18 is received in steady yield 
and of very high radioactive purity. Its increased 
activity diminishes the yield of FDG and in much 
less extent also the purity of last. Synthesis 
yields exhibited high variance connected prob-
ably with quality of disposable cassettes and 
chemicals sets. Most performance non-confor-
mities within the manufacturing cycle occured 
at mechanical nodes of dispensing unit.
From 2286 commercial synthesis there was a 
minimal number of out-of-specification prod-
uct: one with non-compliant pH value and three 
times non-compliant radiochemical purity. The 
in-specification product and total compliance 
of completed batch and in-time requested 
deliveries was 91.9 %. Aseptic conditions have 
been fully preserved during the manufacturing 
period.
Since the pharmaceuticals production is a 
strongly regulated industry, some additional 
merit of further quality systems is usually not 
envisaged. Still the implementation of total 
quality management under ISO 9001 introduc-
es higher assurance for quality production 
performance such as the issues of the 
management responsibility, customer needs 
and satisfaction, contractual arrangement, 
subcontractors’ selection and audit, test/
inspection methodologies, statistical method-
ologies, internal audits, job training, personnel 
competence control, corrective and preventive 
actions, and also costs evaluation in the area 
of failures. These features add value and cred-
itability of the enterprises, which are of sophis-
ticated many-sided character and often 
beginners in the field, like the new radio- 
pharmaceuticals distribution centres in devel-
oping countries.
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